Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease

References

• Afshin-Majd S, Bashiri K, Kiasalari Z, et al. (2017). Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat. Biomed Pharmacother 89:1–9.
   PubMed Web of Science ®Google Scholar
• Ahmad N. (2017). Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease. J Liq Chromatogr Relat Technol 40:677–90.
   Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Naqvi AA, et al. (2017a). Isolation, characterization, and quantification of curcuminoids and their comparative effects in cerebral ischemia. J Liq Chromatogr Relat Technol 40:133–46.
   Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Naqvi AA, et al. (2018). Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia. Artif Cells Nanomed Biotechnol 46:717–29.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad I, Umar S, et al. (2016). PNIPAM nanoparticles for targeted and enhanced nose-to-brain delivery of curcuminoids: UPLC/ESI-Q-ToF-MS/MS-based pharmacokinetics and pharmacodynamic evaluation in cerebral ischemia model. Drug Deliv 23:2095–114.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Al-Subaie AM, Ahmad R, et al. (2019). Brain-targeted glycyrrhizic-acid-loaded surface decorated nanoparticles for treatment of cerebral ischaemia and its toxicity assessment. Artif Cells Nanomed Biotechnol 47:475–90.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Alam MA, Ahmad R, et al. (2017b). Preparation and characterization of surface-modified PLGA-polymeric nanoparticles used to target treatment of intestinal cancer. Artif Cells Nanomed Biotechnol 46:1–15.
   Web of Science ®Google Scholar
• Akilo OD, Choonara YE, Strydom AM, et al. (2016). AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain. Int J Pharm 500:196–209.
   PubMed Web of Science ®Google Scholar
• Bhatia SP, Letizia CS, Api AM. (2008). Fragrance material review on borneol. Food Chem Toxicol 46:S77–S80.
   PubMed Web of Science ®Google Scholar
• Bi C, Wang A, Chu Y, et al. (2016). Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. IJN 11:6547–59.
   Web of Science ®Google Scholar
• Catalan MJ, Molina-Arjona JA, Mir P, et al. (2018). Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. J Neurol 265:1279–87.
   PubMed Web of Science ®Google Scholar
• Chu L, Wang A, Ni L, et al. (2018). Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting. Drug Deliv 25:1634–41.
   PubMed Web of Science ®Google Scholar
• Ehrnhofer-Ressler MM, Fricke K, Pignitter M, et al. (2013). Identification of 1,8-cineole, borneol, camphor, and thujone as anti-inflammatory compounds in a Salvia officinalis L. infusion using human gingival fibroblasts. J Agric Food Chem 61:3451–9.
   PubMed Web of Science ®Google Scholar
• Elfinger M, Maucksch C, Rudolph C. (2007). Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28:3448–55.
   PubMed Web of Science ®Google Scholar
• Elnaggar YSR, Etman SM, Abdelmonsif DA, et al. (2015). Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104:3544–56.
   PubMed Web of Science ®Google Scholar
• Gomes JR, Cabrito I, Soares HR, et al. (2018). Delivery of an anti-transthyretin Nanobody to the brain through intranasal administration reveals transthyretin expression and secretion by motor neurons. J Neurochem 145:393–408.
   PubMed Web of Science ®Google Scholar
• Haque S, Md S, Sahni JK, et al. (2014). Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 48:1–12.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge W. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164–9.
   PubMed Web of Science ®Google Scholar
• Krishna R, Ali M, Moustafa AA. (2014). Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease. Front Aging Neurosci 6:180.
   PubMed Web of Science ®Google Scholar
• Lalani J, Baradia D, Lalani R, et al. (2014). Brain targeted intranasal delivery of tramadol: comparative study of microemulsion and nanoemulsion. Pharm Dev Technol 20:1–10.
   Web of Science ®Google Scholar
• Liu Z, Jiang M, Kang T, et al. (2013). Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration. Biomaterials 34:3870–81.
   PubMed Web of Science ®Google Scholar
• Md S, Khan RA, Mustafa G, et al. (2013). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 48:393–405.
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. (2018). Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. Ijn 13:705–18.
   Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57.
   PubMed Web of Science ®Google Scholar
• Mittal D, Md S, Hasan Q, et al. (2016). Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv 23:130–9.
   PubMed Web of Science ®Google Scholar
• Modi G, Pillay V, Choonara YE, et al. (2009). Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 88:272–85.
   PubMed Web of Science ®Google Scholar
• Muntimadugu E, Dhommati R, Jain A, et al. (2016). Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer's disease. Eur J Pharm Sci 92:224–34.
   PubMed Web of Science ®Google Scholar
• Narayan R, Singh M, Ranjan O, et al. (2016). Development of risperidone liposomes for brain targeting through intranasal route. Life Sci 163:38–45.
   PubMed Web of Science ®Google Scholar
• Owens-Walton C, Jakabek D, Li X, et al. (2018). Striatal changes in Parkinson disease: an investigation of morphology, functional connectivity and their relationship to clinical symptoms. Psychiatry Res 275:5–13.
   PubMed Web of Science ®Google Scholar
• Pahuja R, Seth K, Shukla A, et al. (2015). Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats. ACS Nano 9:4850–71.
   PubMed Web of Science ®Google Scholar
• Qi HP, Gao XC, Zhang LQ, et al. (2013). In vitro evaluation of enhancing effect of borneol on transcorneal permeation of compounds with different hydrophilicities and molecular sizes. Eur J Pharmacol 705:20–5.
   PubMed Web of Science ®Google Scholar
• Ren J, Zou M, Gao P, et al. (2013). Tissue distribution of borneol-modified ganciclovir-loaded solid lipid nanoparticles in mice after intravenous administration. Eur J Pharm Biopharm 83:141–8.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Nogales C, Garbayo E, Carmona-Abellan MM, et al. (2016). Brain aging and Parkinson's disease: new therapeutic approaches using drug delivery systems. Maturitas 84:25–31.
   PubMed Web of Science ®Google Scholar
• Saadati R, Dadashzadeh S, Abbasian Z, et al. (2013). Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm Res 30:985–95.
   PubMed Web of Science ®Google Scholar
• Salat D, Tolosa E. (2013). Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis 3:255–69.
   PubMedGoogle Scholar
• Shin M, Kim HK, Lee H. (2014). Dopamine-loaded poly(D,L-lactic-co-glycolic acid) microspheres: new strategy for encapsulating small hydrophilic drugs with high efficiency. Biotechnol Prog 30:215–23.
   PubMed Web of Science ®Google Scholar
• Suzuki YA, Lopez V, Lonnerdal B. (2005). Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 62:2560–75.
   PubMed Web of Science ®Google Scholar
• Tambe R, Jain P, Patil S, et al. (2016). Antiepileptogenic effects of borneol in pentylenetetrazole-induced kindling in mice. Naunyn Schmiedebergs Arch Pharmacol 389:467–75.
   PubMed Web of Science ®Google Scholar
• Tzeyung A, Md S, Bhattamisra S, et al. (2019). Fabrication, optimization, and evaluation of rotigotine-loaded chitosan nanoparticles for nose-to-brain delivery. Pharmaceutics 11:26.
   PubMed Web of Science ®Google Scholar
• Ungerstedt U. (1971). Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:95–122.
   PubMedGoogle Scholar
• Wen Z, Yan Z, Hu K, et al. (2011). Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration. J Control Release 151:131–8.
   PubMed Web of Science ®Google Scholar
• Yan X, Xu L, Bi C, et al. (2018). Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. IJN 13:273–81.
   Web of Science ®Google Scholar